Uncategorized
Spark Therapeutics reports $16.9 million net loss in third quarter
Spark Therapeutics reported a net loss of $16.9 million, or $0.70 per basic and diluted share, in the third quarter compared with a net loss of $6.8 million, or $1.22 per basic and diluted share, in the same quarter of 2014, according to a press release. Revenue was reported at $1.3 million in the third quarter compared with no revenue reported in the same quarter of 2014. The increase was attributed to a collaboration with Pfizer.